Dec 24, 2019
Correvio Receives Complete Response Letter From U.S. FDA for Brinavess and Provides Update on Recent Events
Dec 11, 2019
Correvio Announces Intention to Explore Strategic Alternatives to Maximize Stakeholder Value
Dec 10, 2019
Correvio Announces Outcome Of FDA Advisory Committee Meeting Reviewing Brinavess(TM) For The Treatment Of Recent Onset Atrial Fibrillation
Dec 10, 2019
Correvio Stock Trading Halted Today; FDA Advisory Committee Meeting To Discuss Brinavess(TM) For Recent Onset Atrial Fibrillation
Nov 18, 2019
Correvio Announces Presentation of New Brinavess(TM) Spectrum Data at the American Heart Association 2019 Annual Meeting
Nov 04, 2019
Correvio Announces FDA Advisory Committee Meeting to Review Brinavess(TM) for Recent Onset Atrial Fibrillation
Aug 12, 2019
Correvio Announces Brinavess® Spectrum Data to be Presented at the European Society of Cardiology 2019 Congress
Jul 25, 2019
U.S. FDA Accepts Correvio's Resubmitted New Drug Application For Brinavess (vernakalant)
Jun 24, 2019
Correvio Resubmits Brinavess (Vernakalant) New Drug Application to U.S. FDA for the Treatment of Patients with Recent Onset Atrial Fibrillation
Jun 18, 2019
Correvio Announces Voting Results
Mar 20, 2019
Correvio Announces Presentation Of Brinavess® Data At The American College Of Cardiology 2019 Annual Meeting
Mar 07, 2019
Correvio to Present at Upcoming Investor Conferences
Feb 21, 2019
Correvio to Participate in the 8th Annual SVB Leerink Global Healthcare Conference
Feb 07, 2019
Correvio Announces Presentation Of Brinavess Data At Belgian Society Of Cardiology 2019 Annual Congress
Nov 20, 2018
Correvio to Present at the 30th Annual Piper Jaffray Healthcare Conference
Oct 30, 2018
Correvio to Report Third Quarter 2018 Financial Results on November 6, 2018
Oct 29, 2018
Correvio Announces Brinavess Eligibility for Patent Extension
Oct 23, 2018
Correvio Announces Intention to Re-File Brinavess® NDA in Second Quarter 2019
Sep 20, 2018
Correvio to Participate In Upcoming Investor Conferences
Sep 05, 2018
Correvio Reports Preliminary Data Collected from >2,000 Brinavess® Treatment Episodes in EU Post-Authorization Safety Study